Product logins

Find logins to all Clarivate products below.


Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast (G7)

The schizophrenia therapy market is crowded and dominated by atypical and typical antipsychotics. Although the continued generic erosion of atypical antipsychotics influences psychiatrists’ treatment decisions, newer oral agents (e.g., Intra-Cellular Therapies’ Caplyta) are aiming to make inroads into the treatment pathway. Competition among LAIs is also intensifying with the availability of new therapies (e.g., Lundbeck / Otsuka’s Abilify Asimtufii, Teva’s Uzedy), along with the generic availability of a few key LAIs. Nevertheless, novel drugs targeting key unmet needs will be welcomed if they clearly differentiate themselves from established therapies to gain a strong foothold in this market. As such, a deep understanding of the current and future dynamics of the schizophrenia therapy market is critical.

Questions answered

  • What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
  • What factors drive and constrain the use of newer-to-market oral and LAIs of atypical antipsychotics? How is competition heating up in these segments?
  • What are the areas of high unmet need in schizophrenia treatment?
  • What improvements would key late-phase therapies need to demonstrate to compete effectively in this market? How will these agents be placed in the schizophrenia treatment algorithm?

Content highlights

Release date: December 2024. Updated throughout the year to reflect Clarivate’s expert analysis of the latest major-market events

Geographies: United States, EU5, Japan

Primary research: 33 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research

Epidemiology: Prevalence of schizophrenia by country, segmented by positive symptoms, negative symptoms, and cognitive impairment; diagnosed / drug-treated prevalence of schizophrenia by country

Forecast: 10-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2033, segmented by brands / generics

Emerging therapies: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents


Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…